Dizal Pharmaceutical received FDA approval for Zegfrovy, a treatment targeting a rare genetic subtype of non-small cell lung cancer. Positioned as a competitor to Johnson & Johnson’s Rybrevant, Dizal claims improved safety and efficacy profiles. The drug addresses patients with specific oncogenic drivers and represents an important addition to precision oncology therapeutics.